Verus Capital Partners LLC Invests $207,000 in Cencora, Inc. $COR

Verus Capital Partners LLC bought a new position in shares of Cencora, Inc. (NYSE:COR) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 690 shares of the company’s stock, valued at approximately $207,000.

A number of other large investors have also modified their holdings of COR. Atlantic Edge Private Wealth Management LLC lifted its stake in Cencora by 70.0% in the 2nd quarter. Atlantic Edge Private Wealth Management LLC now owns 85 shares of the company’s stock valued at $25,000 after buying an additional 35 shares in the last quarter. Obermeyer Wealth Partners boosted its position in shares of Cencora by 1.3% during the 1st quarter. Obermeyer Wealth Partners now owns 2,724 shares of the company’s stock worth $758,000 after purchasing an additional 36 shares during the period. Grove Bank & Trust lifted its position in shares of Cencora by 4.3% during the second quarter. Grove Bank & Trust now owns 879 shares of the company’s stock worth $264,000 after purchasing an additional 36 shares in the last quarter. U.S. Capital Wealth Advisors LLC boosted its holdings in Cencora by 0.4% in the second quarter. U.S. Capital Wealth Advisors LLC now owns 8,547 shares of the company’s stock valued at $2,563,000 after purchasing an additional 38 shares during the period. Finally, Monument Capital Management increased its stake in Cencora by 2.4% in the second quarter. Monument Capital Management now owns 1,637 shares of the company’s stock valued at $491,000 after purchasing an additional 38 shares during the last quarter. Institutional investors and hedge funds own 97.52% of the company’s stock.

Cencora Trading Down 0.0%

NYSE:COR traded down $0.02 during mid-day trading on Thursday, hitting $363.41. The company had a trading volume of 33,019 shares, compared to its average volume of 1,533,230. The company has a debt-to-equity ratio of 3.64, a quick ratio of 0.53 and a current ratio of 0.90. The firm has a market cap of $70.46 billion, a P/E ratio of 37.29, a P/E/G ratio of 1.56 and a beta of 0.63. The business’s fifty day moving average is $318.52 and its two-hundred day moving average is $301.12. Cencora, Inc. has a fifty-two week low of $223.92 and a fifty-two week high of $366.17.

Cencora (NYSE:COR) last issued its quarterly earnings data on Wednesday, November 5th. The company reported $3.84 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.79 by $0.05. The company had revenue of $83.73 billion during the quarter, compared to the consensus estimate of $83.36 billion. Cencora had a net margin of 0.60% and a return on equity of 267.36%. The firm’s revenue was up 5.9% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $3.34 earnings per share. Cencora has set its FY 2026 guidance at 17.450-17.75 EPS. As a group, research analysts expect that Cencora, Inc. will post 15.37 earnings per share for the current year.

Cencora Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, December 1st. Shareholders of record on Friday, November 14th will be paid a $0.60 dividend. This is a positive change from Cencora’s previous quarterly dividend of $0.55. The ex-dividend date is Friday, November 14th. This represents a $2.40 annualized dividend and a yield of 0.7%. Cencora’s dividend payout ratio is presently 30.19%.

Analysts Set New Price Targets

A number of analysts have weighed in on the company. Weiss Ratings reaffirmed a “buy (b-)” rating on shares of Cencora in a research report on Thursday, October 30th. Mizuho increased their price target on Cencora from $340.00 to $380.00 and gave the company an “outperform” rating in a report on Thursday, November 6th. Evercore ISI set a $400.00 price target on shares of Cencora and gave the stock an “outperform” rating in a research report on Thursday, November 6th. JPMorgan Chase & Co. increased their price objective on shares of Cencora from $344.00 to $417.00 and gave the stock an “overweight” rating in a report on Tuesday. Finally, UBS Group boosted their price target on shares of Cencora from $380.00 to $415.00 and gave the stock a “buy” rating in a research report on Friday, November 7th. Nine research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $371.09.

Insider Buying and Selling

In other news, Chairman Steven H. Collis sold 31,350 shares of the company’s stock in a transaction dated Tuesday, September 16th. The shares were sold at an average price of $289.86, for a total transaction of $9,087,111.00. Following the transaction, the chairman owned 305,913 shares in the company, valued at approximately $88,671,942.18. This represents a 9.30% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Robert P. Mauch sold 5,097 shares of the business’s stock in a transaction that occurred on Monday, October 20th. The stock was sold at an average price of $326.80, for a total value of $1,665,699.60. Following the sale, the chief executive officer directly owned 37,940 shares of the company’s stock, valued at $12,398,792. This represents a 11.84% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders sold 41,544 shares of company stock worth $12,230,941. 10.80% of the stock is currently owned by corporate insiders.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.